House dust mite-specific immunoglobulin E antibody (HDM-specific IgE)

House dust mite-specific IgE antibodies are a subset of immunoglobulin E (IgE) produced by B cells in response to exposure to major allergens from house dust mites, primarily *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae* proteins such as Der p 1 and Der p 2[2][5]. These antibodies bind to specific HDM proteins and, upon re-exposure, can trigger cross-linking of IgE on the surface of mast cells and basophils, resulting in degranulation and release of histamine and other mediators, which drive allergic symptoms including asthma, atopic dermatitis, and allergic rhinitis[2][4]. Measurement of HDM-specific IgE in serum is widely used as a **biomarker** for allergic disease diagnosis and patient selection in immunotherapy. However, "house dust mite-specific IgE antibodies" is not itself a receptor, enzyme, or canonical molecular drug target, but rather a class of immunoglobulins defined by specificity, making it technically incorrect to treat it as a conventional "target molecule" in drug discovery[2][4]. The actual molecular targets for therapy are most often (i) the allergens themselves (HDM proteins such as Der p 1, Der p 2, etc.), or (ii) the IgE molecule (targeted by drugs like omalizumab) or its high-affinity receptor FcεRI.

Other names

Allergen-specific IgE (for HDM)HDM-sIgEHouse dust mite sIgE

Immune complex formation with allergen, Binding to FcεRI/FCεRII (CD23) on effector cells, Cross-linking leading to mast cell/basophil degranulation